Overview

A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer

Status:
Active, not recruiting

Trial end date:
2022-08-01

Target enrollment:

Participant gender:

Summary

This study will test whether vaccination with viagenpumatucel-L combined with strategies to modulate the immune response is safe for patients with non-small cell lung adenocarcinoma or squamous cell carcinoma for incurable or metastatic disease.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Heat Biologics

Treatments:

Antibodies, Monoclonal
Nivolumab
Pembrolizumab
Pemetrexed